Therapeutic Research in Multiple Myeloma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Arkansas
ClinicalTrials.gov Identifier:
NCT00572338
First received: December 11, 2007
Last updated: August 12, 2015
Last verified: August 2015

December 11, 2007
August 12, 2015
August 2003
March 2015   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00572338 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Therapeutic Research in Multiple Myeloma
UARK 91-004 Therapeutic Research in Multiple Myeloma

The purpose of this study is to learn how myeloma cells grow and become a cancer, how to distinguish them from normal cells and how to eliminate these cells selectively.

Participating in this study will require that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of your multiple myeloma. Bone marrow/peripheral blood/tissue samples will be collected for research purposes, as well as testing for genetic traits of Castleman's disease if you consent to this study. In addition, data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
  • A bone marrow aspirate and biopsy
  • Blood
  • Fine Needle aspirates
  • Swabs of skin, throat, other sites
Probability Sample

Samples will be studied in the laboratory and in experimental animal models. These analyses and animal models may help to better understand multiple myeloma and to better select the appropriate treatment for all participants with multiple myeloma.

Multiple Myeloma
Other: No drugs are involved
No treatment or drugs are involved in this research. Participating in this study requires that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of participant's multiple myeloma. Bone marrow/peripheral blood samples will be collected at the same time for research purposes. Data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.
Other Name: none, no treatment
patients with myeloma/related diseases
Intervention: Other: No drugs are involved
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
6388
March 2015
March 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Any subject evaluated for a MIRT protocol

Exclusion Criteria:

  • Subjects who have not been evaluated for a MIRT protocol
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00572338
UARK 91-004
No
University of Arkansas
University of Arkansas
Not Provided
Principal Investigator: Bart Barlogie, MD, PhD UAMS Myeloma Institute for Research and Therapy
University of Arkansas
August 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP